{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:29:07Z","timestamp":1793755747690,"version":"4.6.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Rebiotix Inc., a Ferring Company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40265-022-01797-x","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T01:03:21Z","timestamp":1666746201000},"page":"1527-1538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":297,"title":["Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection"],"prefix":"10.1007","volume":"82","clinical-trial-number":[{"clinical-trial-number":"nct03244644","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7619-8338","authenticated-orcid":false,"given":"Sahil","family":"Khanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Assi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Yoho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitfield","family":"Knapple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humberto","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Garcia-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary P.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Marion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindy","family":"Bancke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Feuerstadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"issue":"7","key":"1797_CR1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/cix1085","volume":"66","author":"LC McDonald","year":"2018","unstructured":"McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1\u201348.","journal-title":"Clin Infect Dis"},{"key":"1797_CR2","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.jamda.2022.01.075","volume":"23","author":"P Feuerstadt","year":"2022","unstructured":"Feuerstadt P, Nelson WW, Drozd EM, et al. Mortality, health care use, and costs of Clostridioides difficile infections in older adults. J Am Med Dir Assoc. 2022;23:1721-1728.e19.","journal-title":"J Am Med Dir Assoc"},{"issue":"1","key":"1797_CR3","doi-asserted-by":"publisher","DOI":"10.1017\/ash.2022.2","volume":"2","author":"P Feuerstadt","year":"2022","unstructured":"Feuerstadt P, Nelson WW, Teigland C, et al. Clinical burden of recurrent Clostridioides difficile infection in the medicare population: a real-world claims analysis. Antimicrob Steward Healthc Epidemiol. 2022;2(1): e60.","journal-title":"Antimicrob Steward Healthc Epidemiol."},{"issue":"12","key":"1797_CR4","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.cgh.2011.08.014","volume":"9","author":"JS Bakken","year":"2011","unstructured":"Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"1797_CR5","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","volume":"73","author":"S Johnson","year":"2021","unstructured":"Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021;73(5):e1029\u201344.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1797_CR6","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","volume":"116","author":"CR Kelly","year":"2021","unstructured":"Kelly CR, Fischer M, Allegretti JR, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol. 2021;116(6):1124\u201347.","journal-title":"Am J Gastroenterol"},{"key":"1797_CR7","unstructured":"US Department of Health and Human Services. Guidance for industry. Early clinical trials with live biotherapeutic products: chemistry, manufacturing, and control information. 2016. https:\/\/www.fda.gov\/media\/82945\/download. Accessed 20 Apr 2022."},{"issue":"8","key":"1797_CR8","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1093\/cid\/ciy259","volume":"67","author":"ER Dubberke","year":"2018","unstructured":"Dubberke ER, Lee CH, Orenstein R, et al. Results From a randomized, placebo-controlled clinical trial of a RBX2660: a microbiota-based drug for the prevention of recurrent Clostridium difficile infection. Clin Infect Dis. 2018;67(8):1198\u2013204.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1797_CR9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/cid\/civ938","volume":"62","author":"R Orenstein","year":"2016","unstructured":"Orenstein R, Dubberke E, Hardi R, et al. Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection: results of the PUNCH CD Study. Clin Infect Dis. 2016;62(5):596\u2013602.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1797_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12879-022-07256-y","volume":"22","author":"R Orenstein","year":"2022","unstructured":"Orenstein R, Dubberke ER, Khanna S, et al. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial. BMC Infect Dis. 2022;22(1):245.","journal-title":"BMC Infect Dis"},{"key":"1797_CR11","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1007\/s10620-021-07141-9","volume":"67","author":"P Feuerstadt","year":"2021","unstructured":"Feuerstadt P, Aroniadis OC, Svedlund FL,et al. Heterogeneity of randomized controlled trials of fecal microbiota transplantation in recurrent Clostridioides difficile infection. Dig Dis Sci. 2021;67:2763\u201370.","journal-title":"Dig Dis Sci"},{"issue":"8","key":"1797_CR12","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1093\/cid\/ciy721","volume":"68","author":"R Tariq","year":"2019","unstructured":"Tariq R, Pardi DS, Bartlett MG, et al. Low cure rates in controlled trials of fecal microbiota transplantation for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Clin Infect Dis. 2019;68(8):1351\u20138.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1797_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.7326\/M16-2810","volume":"167","author":"A Bafeta","year":"2017","unstructured":"Bafeta A, Yavchitz A, Riveros C, et al. Methods and reporting studies assessing fecal microbiota transplantation: a systematic review. Ann Intern Med. 2017;167(1):34\u20139.","journal-title":"Ann Intern Med"},{"issue":"14","key":"1797_CR14","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","volume":"382","author":"AY Guh","year":"2020","unstructured":"Guh AY, Mu Y, Winston LG, et al. Trends in U.S. Burden of Clostridioides difficile infection and outcomes. N Engl J Med. 2020;382(14):1320\u201330.","journal-title":"N Engl J Med"},{"issue":"3","key":"1797_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa2106516","volume":"386","author":"P Feuerstadt","year":"2022","unstructured":"Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med. 2022;386(3):220\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"1797_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jhin.2015.10.024","volume":"92","author":"M Baxter","year":"2016","unstructured":"Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the literature. J Hosp Infect. 2016;92(2):117\u201327.","journal-title":"J Hosp Infect"},{"issue":"6","key":"1797_CR17","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1053\/j.gastro.2021.01.010","volume":"160","author":"S Saha","year":"2021","unstructured":"Saha S, Mara K, Pardi DS, et al. Long-term safety of fecal microbiota transplantation for recurrent Clostridioides difficile infection. Gastroenterology. 2021;160(6):1961\u20139.e3.","journal-title":"Gastroenterology"},{"issue":"21","key":"1797_CR18","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","volume":"381","author":"Z DeFilipp","year":"2019","unstructured":"DeFilipp Z, Bloom PP, Torres Soto M, et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med. 2019;381(21):2043\u201350.","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1007\/s40265-022-01805-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01797-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01797-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01797-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T09:19:28Z","timestamp":1683796768000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01797-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":18,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1797"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01797-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"19 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-022-01805-0","URL":"https:\/\/doi.org\/10.1007\/s40265-022-01805-0","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rebiotix Inc., a Ferring Company, provided financial support for this work. The study protocol was developed by Rebiotix Inc., a Ferring Company, in collaboration with the study investigators. Rebiotix Inc. was also involved in data collection, analysis, and interpretation of results. Statistical analyses were performed by statisticians at Rebiotix Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sahil Khanna has received grants or contracts from Rebiotix (a Ferring company), Finch Therapeutics, Seres Therapeutics, and Vedanta BioSciences, consulting fees from Niche Pharmaceuticals and Immuron Limited, participated on advisory or data safety monitoring boards for Ferring Pharmaceuticals, and has stock options with Jetson Probiotics. Christine Lee has received grants or contracts from Rebiotix, Inc., Seres Therapeutics, and Summit Therapeutic and participated on advisory or data safety monitoring boards for Ferring Pharmaceuticals and Pfizer. Thomas Louie has received consulting fees from Crestone, MGB BioPharma, Rebiotix, Inc., and Seres Therapeutics and participated on advisory boards for Seres Therapeutics and Vedanta BioSciences. Scott M. Berry has ownership in Berry Consultants who received fees for trial design and analyses; Tricia Braun, Lindy Bancke, and Xin Su are employees of Rebiotix, Inc. or were during conduct of the study. Paul Feuerstadt has received consulting fees from Rebiotix, Inc. and Takeda Pharmaceuticals, honoraria from Ferring Pharmaceuticals, Seres Therapeutics, and Takeda Pharmaceuticals, and participated on advisory or data safety monitoring boards for Ferring Pharmaceuticals, Seres Therapeutics, and Takeda Pharmaceuticals. Humberto Aguilar, Maha Assi, Julia Garcia-Diaz, Whitfield Knapple, Gary P. Wang, and David Yoho have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"All procedures performed in studies involving participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated and\/or analyzed during the current study are not publicly available because of pending regulatory submission and approval but may be available from the corresponding author on request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"SK, LB, and SMB conceptualized and designed the study. SMB, LB, TB, JM, and XS designed and conducted the statistical analyses and vouch for the data. All authors were involved in the acquisition, analysis, or interpretation of the data. Under the guidance from all authors, medical writers Regina Switzer, PhD (paid for by Rebiotix Inc.), and Michelle Boland, PhD (ApotheCom, Yardley, PA, USA; paid for by Ferring Pharmaceuticals) assisted with the drafting of the manuscript. All authors provided critical revision of the manuscript, and all agreed to the submission of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}